<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853905</url>
  </required_header>
  <id_info>
    <org_study_id>07-827</org_study_id>
    <nct_id>NCT00853905</nct_id>
  </id_info>
  <brief_title>Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?</brief_title>
  <official_title>The Effect of Intracameral Triesence (Triamcinolone Acetonide Injectable Suspension) on Ocular Inflammation After Trabeculectomy, Tube Shunt Implantation or Combined Trabeculectomy With Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that intracameral Triesence during glaucoma surgery will
      provide lower intraocular pressure through better control of ocular inflammation, thus
      leading to a more successful filtering procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Determine the efficacy and safety of intracameral Triesence in patients who undergo
      trabeculectomy, tube shunt, or combined cataract extraction, intra-ocular lens implantation
      and trabeculectomy with or without adjunctive mitomycin-C.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>Data collected Baseline (before Surgery), 1 day, 1week, 1 month, 3 month and 6 month post-op visits</time_frame>
    <description>patient failed the study if IOP was less than 5mmhg for starting IOP or less than a 20% decrease in IOP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A Kowa FM-500 Flare Meter is Used to Measure Inflammation in the Anterior Chamber</measure>
    <time_frame>Data collected 1 month, 3 month and 6 month post-op visits</time_frame>
    <description>Anterior chamber inflammation measurement is taken 10 times using the Kowa FM-500 flare meter per eye</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleb Morphology Graded by Indiana Bleb Appearance Grading Scale (IBAGS) and the Moorfields Bleb Grading System (MBGS)</measure>
    <time_frame>IBAGS assessed at 1 day, 1 week, 1 month, 3 month and 6 month post-op visits; Moorfields Bleb Grading will be done at 1 month, 3 month, and 6 month post-op visits</time_frame>
    <description>Bleb appearance is grading using the Moorfields bleb grading system IBAGS; anterior segment slit lamp photos were also done</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A Patient Comfort Questionnaire</measure>
    <time_frame>Patients will be quiered at 1 day, 1 week, 1 month, 3 month and 6 month post-op visit</time_frame>
    <description>Dry Eye Scores were lower in the treatment group at 1 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Hypotensive Medications</measure>
    <time_frame>Ocular medications will be documented during the 1 day, 1 week, 1 month, 3 month, and or 6 month post-operative period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Treatment 1(Triesence)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.2cc Triesence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 2 (balanced salt solution BSS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>glaucoma surgery with balanced salt solution, the standard technique used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triesence</intervention_name>
    <description>At the end of standard glaucoma surgery after the anterior chamber is reformed with balanced salt solution or viscoelastic to adequate intraocular pressure; 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound</description>
    <arm_group_label>Treatment 1(Triesence)</arm_group_label>
    <other_name>triamcinolone acetonide injectable</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>balanced salt solution BSS</intervention_name>
    <description>standard technique for glaucoma surgery . At the end of the case anterior chamber will be reformed with balanced salt solution to adequate intraocular pressure.</description>
    <arm_group_label>Treatment 2 (balanced salt solution BSS)</arm_group_label>
    <other_name>balanced salt solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  glaucoma patients requiring surgery (Trabeculectomy or Express Shunt; Trabeculectomy
             plus Phacoemulsification and Interocular Lens Implant; Baerveldt Tube; Ahmed Tube;
             Molteno Tube)

          -  primary open angle glaucoma

          -  primary angle-closure glaucoma

          -  pseudoexfoliation glaucoma

          -  pigmentary glaucoma

          -  traumatic glaucoma

          -  neovascular glaucoma

        Exclusion Criteria:

          -  patients that are pregnant, nursing, or not using adequate contraception

          -  any other eye surgery except cataract surgery

          -  an infection, inflammation, or any abnormality preventing measurement of eye pressure

          -  enrolled in another investigational study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlene R Moster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2009</study_first_submitted>
  <study_first_submitted_qc>February 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2009</study_first_posted>
  <results_first_submitted>February 12, 2015</results_first_submitted>
  <results_first_submitted_qc>March 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 21, 2016</results_first_posted>
  <last_update_submitted>November 20, 2016</last_update_submitted>
  <last_update_submitted_qc>November 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Marlene Moster, MD</investigator_full_name>
    <investigator_title>Attending Surgeon Wills Eye Institute; Professor Jefferson Medical College</investigator_title>
  </responsible_party>
  <keyword>open angle glaucoma (POAG)</keyword>
  <keyword>angle closure glaucoma (PACG)</keyword>
  <keyword>pigmentary glaucoma</keyword>
  <keyword>pseudoexfoliation glaucoma</keyword>
  <keyword>neovascular glaucoma</keyword>
  <keyword>traumatic glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>April 2009 to July 2011 at the Wills Eye Hospital</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment 1(Triesence)</title>
          <description>0.2cc Triesence
Triesence: At the end of standard glaucoma surgery after the anterior chamber is reformed with balanced salt solution or viscoelastic to adequate intraocular pressure; 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound</description>
        </group>
        <group group_id="P2">
          <title>Treatment 2 (Balanced Salt Solution BSS)</title>
          <description>glaucoma surgery with balanced salt solution, the standard technique used.
balanced salt solution BSS: standard technique for glaucoma surgery . At the end of the case anterior chamber will be reformed with balanced salt solution to adequate intraocular pressure.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>never had surgery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment 1(Triesence)</title>
          <description>0.2cc Triesence
Triesence: At the end of standard glaucoma surgery after the anterior chamber is reformed with balanced salt solution or viscoelastic to adequate intraocular pressure; 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound</description>
        </group>
        <group group_id="B2">
          <title>Treatment 2 (Balanced Salt Solution BSS)</title>
          <description>glaucoma surgery with balanced salt solution, the standard technique used.
balanced salt solution BSS: standard technique for glaucoma surgery . At the end of the case anterior chamber will be reformed with balanced salt solution to adequate intraocular pressure.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="47" upper_limit="88"/>
                    <measurement group_id="B2" value="69" lower_limit="42" upper_limit="88"/>
                    <measurement group_id="B3" value="68.5" lower_limit="42" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Interocular Pressure (mmHg)</title>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.5" lower_limit="13" upper_limit="40"/>
                    <measurement group_id="B2" value="23.8" lower_limit="8.5" upper_limit="56"/>
                    <measurement group_id="B3" value="24.0" lower_limit="8.5" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intraocular Pressure (IOP)</title>
        <description>patient failed the study if IOP was less than 5mmhg for starting IOP or less than a 20% decrease in IOP</description>
        <time_frame>Data collected Baseline (before Surgery), 1 day, 1week, 1 month, 3 month and 6 month post-op visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment 1(Triesence)</title>
            <description>0.2cc Triesence
Triesence: At the end of standard glaucoma surgery after the anterior chamber is reformed with balanced salt solution or viscoelastic to adequate intraocular pressure; 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound</description>
          </group>
          <group group_id="O2">
            <title>Treatment 2 (Balanced Salt Solution BSS)</title>
            <description>glaucoma surgery with balanced salt solution, the standard technique used.
balanced salt solution BSS: standard technique for glaucoma surgery . At the end of the case anterior chamber will be reformed with balanced salt solution to adequate intraocular pressure.</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (IOP)</title>
          <description>patient failed the study if IOP was less than 5mmhg for starting IOP or less than a 20% decrease in IOP</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5" lower_limit="13" upper_limit="40"/>
                    <measurement group_id="O2" value="23.8" lower_limit="8.5" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="13.1" upper_limit="19.05"/>
                    <measurement group_id="O2" value="12.8" lower_limit="10.7" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" lower_limit="9.1" upper_limit="14.5"/>
                    <measurement group_id="O2" value="11.8" lower_limit="9.8" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" lower_limit="13.0" upper_limit="19.4"/>
                    <measurement group_id="O2" value="14.4" lower_limit="12.2" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" lower_limit="12.2" upper_limit="18.4"/>
                    <measurement group_id="O2" value="12.8" lower_limit="10.7" upper_limit="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="11.7" upper_limit="17.8"/>
                    <measurement group_id="O2" value="13.6" lower_limit="11.5" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>A Kowa FM-500 Flare Meter is Used to Measure Inflammation in the Anterior Chamber</title>
        <description>Anterior chamber inflammation measurement is taken 10 times using the Kowa FM-500 flare meter per eye</description>
        <time_frame>Data collected 1 month, 3 month and 6 month post-op visits</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleb Morphology Graded by Indiana Bleb Appearance Grading Scale (IBAGS) and the Moorfields Bleb Grading System (MBGS)</title>
        <description>Bleb appearance is grading using the Moorfields bleb grading system IBAGS; anterior segment slit lamp photos were also done</description>
        <time_frame>IBAGS assessed at 1 day, 1 week, 1 month, 3 month and 6 month post-op visits; Moorfields Bleb Grading will be done at 1 month, 3 month, and 6 month post-op visits</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>A Patient Comfort Questionnaire</title>
        <description>Dry Eye Scores were lower in the treatment group at 1 month</description>
        <time_frame>Patients will be quiered at 1 day, 1 week, 1 month, 3 month and 6 month post-op visit</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Hypotensive Medications</title>
        <time_frame>Ocular medications will be documented during the 1 day, 1 week, 1 month, 3 month, and or 6 month post-operative period</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>surgery, day 1, 1 week, 1 month, 3 month, 6 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment 1(Triesence)</title>
          <description>0.2cc Triesence
Triesence: At the end of standard glaucoma surgery after the anterior chamber is reformed with balanced salt solution or viscoelastic to adequate intraocular pressure; 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound</description>
        </group>
        <group group_id="E2">
          <title>Treatment 2 (Balanced Salt Solution BSS)</title>
          <description>glaucoma surgery with balanced salt solution, the standard technique used.
balanced salt solution BSS: standard technique for glaucoma surgery . At the end of the case anterior chamber will be reformed with balanced salt solution to adequate intraocular pressure.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>IOP failure</sub_title>
                <description>IOP failed to drop 20% or less than a 5mmhg drop from original IOP; eye drops added</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>choroidals drained; A/C reformed</sub_title>
                <description>patient needed another glaucoma procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marlene Moster MD</name_or_title>
      <organization>Wills Eye Hospital Glaucoma Research</organization>
      <phone>215-825-4713</phone>
      <email>jmolineaux@willseye.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

